$ATHX News

Last published 3y ago

3y agoATHXAthersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic AlternativesBusiness WireAthersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a
3y agoATHXAthersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with HealiosBusiness WireThe MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical
3y agoATHXAthersys Licenses its Animal Health Assets to Ardent Animal HealthBusiness WireAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for
3y agoATHX RIGL SLSAthersys Director Jane Wasman Appointed Board ChairBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company's recent 2023
3y agoATHXGrant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney TransplantationBusiness WireAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at
3y agoATHXAthersys, Inc. Announces Pricing of $3.5 Million Public OfferingBusiness WireAthersys, Inc. (NASDAQ:ATHX), today announced the pricing of its "reasonable best efforts" public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32
3y agoATHXAthersys Reports Second Quarter 2023 Financial Results and Business HighlightsBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June
3y agoATHXAthersys Appoints Neema Mayhugh, PhD to its Board of DirectorsBusiness WireHealthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem®
3y agoATHXAthersys to Host Business Update Conference Call on August 9thBusiness WireAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on
3y agoATHXPatient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem® Following Hemorrhagic TraumaBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort
3y agoATHXAthersys Restructures Debt with SupplierBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier
3y agoATHXAthersys Reports First Quarter 2023 Financial Results and Business HighlightsBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months
3y agoATHXAthersys to Participate in Three Upcoming ConferencesBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences during
3y agoATHXAthersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care ConferenceBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in
3y agoATHXAthersys to Participate in The American Society for Neural Therapy and Repair Annual ConferenceBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural
3y agoATHXAthersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private PlacementBusiness WireAthersys, Inc. (NASDAQ:ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the "Shares") of the Company's common stock (or common stock equivalents in lieu thereof) in a
3y agoATHXAthersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private PlacementBusiness WireAthersys, Inc. (NASDAQ:ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the "Shares") of the Company's common stock (or common stock equivalents in lieu
3y agoATHXAthersys to Host Business Update Conference Call on April 20thBusiness WireAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on
3y agoATHXAthersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsBusiness WireAthersys, Inc. (NASDAQ:ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update. Fourth Quarter 2022 and Recent Corporate and Operational
3y agoATHXAthersys Announces Successful Type B Meeting with the FDABusiness WirePrimary Endpoint in Pivotal Acute Ischemic Stroke Trial Will Become mRS Shift Analysis at Day 365 Modifications Reflect Observations from Healios' Recently Completed TREASURE Trial in Japan and the Evolution of
3y agoATHXAthersys Expands IP Protection with First New Patent for SIFU® TechnologyBusiness WireNovel Ultracold Storage System Ready for Commercial Licensing Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications,
3y agoATHXAthersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol DiscussionBusiness WireAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the Company has been granted a clinical Type
3y agoATHX IMMR NNDM SSYS+4Murchinson Issues Letter to Fellow Shareholders Regarding the Urgent Need for Boardroom Change at Nano DimensionBusiness WireBelieves the Stern-Controlled Board's Decision to Challenge Our Special Meeting Demand – Without Any Valid Justification – Reinforces the Need for Objective and Independent Perspectives in the Boardroom Contends the
3y agoATHXAthersys to Host Business Update Conference Call on February 14thBusiness WireAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on
3y agoATHXAthersys to Participate in International Stroke Conference and BioProcess InternationalBusiness WireAthersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two upcoming conferences, the
3y agoATHXAthersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in JanuaryBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies
3y agoATHXAthersys Provides MultiStem Clinical UpdateBusiness WireEnrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company
3y agoATHXAthersys Appoints Joseph Nolan to Its Board of DirectorsBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph "Joe" Nolan to its Board of Directors,
3y agoATHXAthersys Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness WireCorporate restructuring largely complete, enrollment in MASTERS-2 clinical trial accelerates Conference call begins at 11:00 a.m. Eastern time today Athersys, Inc. (NASDAQ:ATHX) announced today its financial results
4y agoATHXAthersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.'s Biotech ConferenceBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and
4y agoATHXAthersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public OfferingBusiness WireAthersys, Inc. (NASDAQ:ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of
4y agoATHXAthersys Reschedules Third Quarter Conference Call to November 15Business WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file its quarterly report on Form 10-Q for the
4y agoATHXAthersys, Inc. Announces Pricing of $5.5 Million Public OfferingBusiness WireAthersys, Inc. (NASDAQ:ATHX) ("Athersys" or the "Company") today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of common stock (or common stock equivalents)
4y agoATHXAthersys, Inc. Announces Proposed Public OfferingBusiness WireAthersys, Inc. (NASDAQ:ATHX) ("Athersys" or the "Company") today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common
4y agoATHXAthersys to Host Third Quarter Financial Results CallBusiness WireAthersys, Inc. (NASDAQ:ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results. Members of the management team will host the
4y agoATHXAthersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in OctoberBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two October conferences, the 2022 Cell & Gene Meeting on the Mesa on October 11-13
4y agoATHXAthersys to Host Business Update Conference Call on October 6thBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, C
4y agoATHXAthersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct OfferingBusiness WireProvides Additional Financial Flexibility in Exchange for New Warrants with a $6.385 Exercise Price Company to hold a business update conference call the week of October 3rd Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing
4y agoATHXAthersys Announces 1-for-25 Reverse Stock SplitBusiness WireAthersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1
4y agoATHXAthersys, Inc. Announces Closing of $12 Million Registered Direct OfferingBusiness WireAthersys, Inc. (NASDAQ:ATHX) today announced the closing of its previously announced registered direct offering with a single healthcare-focused U.S. institutional investor for the purchase of 48,000,000 shares of the Company's common stock (or common s
4y agoATHXAthersys, Inc. Announces $12 Million Registered Direct OfferingBusiness WireAthersys, Inc. (NASDAQ:ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares of the Company's common stock (or common stock equiv
4y agoATHXAthersys Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness WireCorporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three and six months ended June 30, 2022 an
4y agoATHXAthersys (ATHX) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsATHX earnings call for the period ending June 30, 2022.
4y agoATHXAthersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple IndicationsBusiness WireAthersys, Inc. (NASDAQ:ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services Un
4y agoATHXAthersys Appoints Kasey Rosado as Interim Chief Financial OfficerBusiness WireBrings Operational Excellence and Financial Experience to Leadership Team Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces today its engagement with Ankura C
4y agoATHXAthersys to Host Second Quarter Financial Results CallBusiness WireAthersys, Inc. (NASDAQ:ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.
4y agoATHXAthersys and Aspire Capital Fund Terminate RelationshipBusiness WireAthersys, Inc. (NASDAQ:ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company continues to evaluate alternative financing options to support continuing operations. After se
4y agoATHXAthersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director DeparturesBusiness WireAthersys, Inc. (NASDAQ:ATHX) today announced the Company's slate of director candidates for its 2022 Annual Meeting of Stockholders being held on Thursday, July 28, 2022, at 8:30 a.m. ET. As previously announced, in connection with the Company's cost-cu
4y agoATHXAthersys Postpones Annual Meeting of StockholdersBusiness WireAnnual Meeting of Stockholders rescheduled to Thursday, July 28, 2022, 8:30 a.m. ET Athersys, Inc. (NASDAQ:ATHX) today announced the postponement of its Annual Meeting of Stockholders, initially scheduled for Wednesday, June 15, 2022, at 8:30 a.m. ET
4y agoATHXAthersys Hosting KOL Panel Event to Discuss TREASURE DataBusiness WireWebinar scheduled for June 14, 2022 at 5:00 p.m. ET Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a panel discussion with leading neuro